Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine.
📄 Abstract
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition of glycogen synthase kinase 3 beta (
Confidence:
0.19
· 4 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
—
0.00
In silico
Network pharmacology analysis of cellular targets in MDD and differential mechanisms of fluoxetine, ketamine and esketamine
0.90
Genetic association
GWAS identified genetic loci associated with MDD; astrocyte fatty acid metabolism as a risk factor
0.90
Ex vivo
—
0.00
Animal model
—
0.00
Diet/model
—
0.00
Клиника (11 полей)
Drug
fluoxetine, ketamine, esketamine
0.90
Indication
major depressive disorder
0.90
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00